Steven I. Sherman

Steven I. Sherman, MD is Professor and Deputy Division Head ad Interim of the Department of Endocrine Neoplasia and Hormonal Disorders at MD Anderson Cancer Center, where he has led thyroid oncology research for over three decades. He is one of the most prolific and influential investigators in thyroid cancer clinical pharmacology, having contributed to the development and approval of virtually every major targeted agent used in advanced thyroid cancers, including lenvatinib, sorafenib, vandetanib, cabozantinib, and the selective RET inhibitors. Dr. Sherman served as a principal investigator of SELECT, the landmark phase III trial of lenvatinib in RAI-refractory differentiated thyroid cancer published in the New England Journal of Medicine in 2015. He has also contributed to DECISION (sorafenib) and multiple early-phase trials establishing new standards of care for differentiated, medullary, and anaplastic thyroid cancers. His work on the biology of thyroid cancer progression, including loss of iodine avidity and mechanisms of dedifferentiation, has informed therapeutic redifferentiation strategies. Beyond clinical trials, Dr. Sherman has made seminal contributions to thyroid cancer staging, risk stratification, and surveillance strategies. He has served on the American Thyroid Association, NCCN, and ESMO guideline committees and is a past president of the American Thyroid Association. His publication record spans over 350 peer-reviewed papers.